HIPRA is the only pharmaceutical company to have 2 vaccines against bovine mastitis registered by the EMA, highlighting the quality, efficacy and safety of our vaccines.
At HIPRA we are celebrating 10 years since the first registration and successful launch of STARTVAC®, the first bovine mastitis vaccine registered by the European Medicines Agency (EMA).
Over the years, we have witnessed how the dairy industry has evolved towards better control and management of farms with the aim of increasing quality and productivity.
The new policies and regulations to reduce the use of antibiotics in production animals, together with the fluctuation in milk prices and increased competition, have resulted in new solutions based on competitiveness.
Moreover, vaccination against bovine mastitis plays an important role and is included as an additional recommendation in mastitis control programmes (M2 Magazine link, Hemling, 2018).
Following these changes, it is estimated today that most practitioners dealing with dairy cattle recommend vaccinating with STARTVAC® as a novel solution in the prevention of mastitis.
STARTVAC® is the global leader in mastitis vaccines, accounting for more than 60% of global mastitis vaccine sales.
For this reason, STARTVAC® is the global leader in mastitis vaccines, accounting for more than 60% of global mastitis vaccine sales. Since its launch in 2009, STARTVAC® has been marketed in 59 countries around the world, becoming a leading vaccine in mastitis prevention worldwide.
Apart from European countries, the vaccine is also available in other key dairy markets such as Japan, South Korea, Brazil, Mexico, Canada, Turkey, New Zealand and South Africa.
Our latest milestone, the registration of UBAC® vaccine against mastitis caused by Strep. Uberis
At HIPRA, as part of our commitment to the fight against mastitis, we not only offer a highly competitive vaccine, but we also provide clients with technical services and diagnostic tools in order to improve their economic results.
The latest milestone at HIPRA in the prevention of mastitis has been the registration of UBAC®, the only specific vaccine against mastitis caused by Strep. Uberis, registered by the European Medicines Agency in 2018.
HIPRA is the only veterinary pharmaceutical company to have two vaccines against bovine mastitis registered by the European Medicines Agency, highlighting the quality, efficacy and safety of our vaccines.
